MCID: ADN010
MIFTS: 46

Adenosquamous Cell Lung Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Adenosquamous Cell Lung Carcinoma

MalaCards integrated aliases for Adenosquamous Cell Lung Carcinoma:

Name: Adenosquamous Cell Lung Carcinoma 12 15
Adenosquamous Cell Lung Cancer 73
Adenosquamous Lung Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4829
NCIt 50 C9133
UMLS 73 C0279557

Summaries for Adenosquamous Cell Lung Carcinoma

MalaCards based summary : Adenosquamous Cell Lung Carcinoma, also known as adenosquamous cell lung cancer, is related to rare adenocarcinoma of the breast and sigmoid neoplasm. An important gene associated with Adenosquamous Cell Lung Carcinoma is KIF5B (Kinesin Family Member 5B), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung and brain, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Adenosquamous Cell Lung Carcinoma

Diseases related to Adenosquamous Cell Lung Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 rare adenocarcinoma of the breast 10.8 KRAS PIK3CA
2 sigmoid neoplasm 10.8 HRAS KRAS
3 kyasanur forest disease 10.8 ALK KRAS
4 prostate adenoid cystic carcinoma 10.8 HRAS PIK3CA
5 schimmelpenning-feuerstein-mims syndrome 10.7 HRAS KRAS
6 periampullary adenoma 10.6 HRAS KRAS
7 dermatosis papulosa nigra 10.6 FGFR3 PIK3CA
8 benign struma ovarii 10.6 HRAS RET
9 bile duct cysts 10.6 HRAS KRAS
10 ethmoid sinus cancer 10.6 EGFR HRAS PIK3CA
11 ethmoid sinus adenocarcinoma 10.6 EGFR HRAS PIK3CA
12 apocrine adenoma 10.6 HRAS KRAS PIK3CA
13 aggressive digital papillary adenocarcinoma 10.6 HRAS KRAS PIK3CA
14 breast intraductal proliferative lesion 10.6 EGFR ERBB2
15 skin squamous cell carcinoma 10.5 HRAS KRAS PIK3CA
16 bronchiolo-alveolar adenocarcinoma 10.5 EGFR KRAS
17 paronychia 10.5 EGFR HRAS KRAS
18 parotid gland cancer 10.5 ALK PIK3CA RET
19 intracystic papillary adenoma 10.5 EGFR ERBB2
20 progesterone-receptor negative breast cancer 10.5 EGFR ERBB2
21 colorectal adenocarcinoma 10.4 EGFR HRAS KRAS
22 renal hypodysplasia/aplasia 3 10.4 FGFR3 RET
23 breast scirrhous carcinoma 10.4 EGFR ERBB2
24 spinal chordoma 10.4 EGFR PDGFRA PIK3CA
25 secondary hypertrophic osteoarthropathy 10.4 HRAS KRAS
26 pilocytic astrocytoma 10.4 HRAS KRAS PIK3CA
27 cell type benign neoplasm 10.4 HRAS KRAS RET
28 oncocytic breast carcinoma 10.4 EGFR ERBB2
29 multiple mucosal neuroma 10.3 ENO2 RET
30 malignant ectomesenchymoma 10.3 ENO2 HRAS
31 breast squamous cell carcinoma 10.3 EGFR ERBB2 PIK3CA
32 estrogen-receptor positive breast cancer 10.3 EGFR ERBB2 PIK3CA
33 nasal cavity adenocarcinoma 10.2 HRAS KRAS
34 serous cystadenocarcinoma 10.2 ERBB2 HRAS PIK3CA
35 ectomesenchymoma 10.2 ENO2 HRAS
36 oral cavity cancer 10.2 EGFR ERBB2 PIK3CA
37 small intestinal adenocarcinoma 10.2 EGFR ERBB2 KRAS
38 cystadenocarcinoma 10.2 ERBB2 HRAS PIK3CA
39 neurofibromatosis, type iv, of riccardi 10.2 HRAS PDGFRA RET
40 ovarian serous cystadenocarcinoma 10.2 ERBB2 HRAS PIK3CA
41 ovary adenocarcinoma 10.2 ERBB2 HRAS KRAS
42 thyroid cancer, nonmedullary, 2 10.2 HRAS PIK3CA RET
43 endometrial adenocarcinoma 10.2 EGFR ERBB2 KRAS
44 malignant peripheral nerve sheath tumor 10.2 EGFR NRG1 PDGFRA
45 pulmonary large cell neuroendocrine carcinoma 10.2 ENO2 ROS1
46 primary peritoneal carcinoma 10.2 EGFR ERBB2 RET
47 mucinous adenocarcinoma 10.1 ALK EGFR KRAS NRG1
48 duodenum cancer 10.1 ENO2 HRAS KRAS
49 breast adenoid cystic carcinoma 10.1 EGFR ERBB2
50 liver angiosarcoma 10.1 ENO2 HRAS KRAS

Graphical network of the top 20 diseases related to Adenosquamous Cell Lung Carcinoma:



Diseases related to Adenosquamous Cell Lung Carcinoma

Symptoms & Phenotypes for Adenosquamous Cell Lung Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 60)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.28 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 11.28 KRAS
3 Decreased viability GR00173-A 11.28 PDGFRA
4 Decreased viability GR00221-A-1 11.28 EGFR FGFR3 KRAS HRAS PDGFRA ARAF
5 Decreased viability GR00221-A-2 11.28 FGFR3 KRAS HRAS DDR2 PIK3CA RET
6 Decreased viability GR00221-A-3 11.28 ERBB2 FGFR3 HRAS PDGFRA
7 Decreased viability GR00221-A-4 11.28 EGFR ERBB2 ARAF DDR2 ALK PDGFRA
8 Decreased viability GR00231-A 11.28 RET
9 Decreased viability GR00301-A 11.28 KRAS RET
10 Decreased viability GR00342-S-1 11.28 ARAF ROS1
11 Decreased viability GR00342-S-2 11.28 ARAF
12 Decreased viability GR00342-S-3 11.28 ARAF
13 Decreased viability GR00381-A-1 11.28 KRAS
14 Decreased viability GR00402-S-2 11.28 ERBB2 EGFR FGFR3 KRAS HRAS PDGFRA
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.22 FGFR3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.22 ERBB2
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 10.22 RET
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.22 RET
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.22 PIK3CA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.22 RET
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.22 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.22 FGFR3
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.22 ERBB2 FGFR3 PIK3CA RET
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.22 ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.21 DDR2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.21 DDR2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.21 FGFR3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.21 EGFR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.21 EGFR FGFR3
30 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.21 RET
31 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.21 RET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 DDR2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.21 ERBB2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.21 ERBB2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.21 RET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.21 ERBB2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.21 DDR2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.21 RET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.21 DDR2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.21 EGFR
41 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.21 ERBB2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.21 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 EGFR
44 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.21 DDR2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.21 RET
46 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.21 ERBB2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 DDR2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.21 EGFR
49 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.21 FGFR3 RET
50 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.21 FGFR3 ERBB2

MGI Mouse Phenotypes related to Adenosquamous Cell Lung Carcinoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.36 ERBB2 HRAS KIF5B FGFR3 KRAS PDGFRA
2 cellular MP:0005384 10.34 ERBB2 KIF5B FGFR3 KRAS PIK3CA PDGFRA
3 behavior/neurological MP:0005386 10.27 FGFR3 HRAS ERBB2 ENO2 KRAS PIK3CA
4 endocrine/exocrine gland MP:0005379 10.26 ERBB2 HRAS KIF5B KRAS PIK3CA PDGFRA
5 mortality/aging MP:0010768 10.25 ERBB2 HRAS KIF5B FGFR3 KRAS PIK3CA
6 homeostasis/metabolism MP:0005376 10.24 FGFR3 HRAS ERBB2 KIF5B KRAS PIK3CA
7 craniofacial MP:0005382 10.15 ERBB2 HRAS FGFR3 KRAS PDGFRA EGFR
8 digestive/alimentary MP:0005381 10.14 ERBB2 HRAS FGFR3 KRAS RET PDGFRA
9 integument MP:0010771 10.13 ERBB2 HRAS FGFR3 KRAS PIK3CA PDGFRA
10 neoplasm MP:0002006 10.07 ERBB2 HRAS FGFR3 KRAS PDGFRA RET
11 nervous system MP:0003631 10.06 ERBB2 HRAS FGFR3 KRAS PIK3CA RET
12 muscle MP:0005369 10.01 ERBB2 KRAS PIK3CA RET PDGFRA ARAF
13 limbs/digits/tail MP:0005371 10 FGFR3 ERBB2 KRAS RET PDGFRA EGFR
14 no phenotypic analysis MP:0003012 9.91 HRAS FGFR3 KRAS PIK3CA PDGFRA RET
15 reproductive system MP:0005389 9.85 ERBB2 FGFR3 PIK3CA PDGFRA RET KRAS
16 respiratory system MP:0005388 9.61 ERBB2 HRAS FGFR3 KRAS PDGFRA RET
17 skeleton MP:0005390 9.32 ERBB2 HRAS FGFR3 KRAS PIK3CA PDGFRA

Drugs & Therapeutics for Adenosquamous Cell Lung Carcinoma

Drugs for Adenosquamous Cell Lung Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
4
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
5
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
7
Vinblastine Approved Phase 3,Phase 1 865-21-4 13342 241903
8
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
9
Vinorelbine Approved, Investigational Phase 3,Phase 1 71486-22-1 60780 44424639
10
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
11
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
12
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
13
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
14
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
16
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
17 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
18 Vitamin B Complex Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 3,Phase 2,Phase 1
21 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
22 Antimetabolites Phase 3,Phase 2,Phase 1
23 Antiviral Agents Phase 3,Phase 2,Phase 1
24 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
25 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Mitogens Phase 3,Phase 2
27 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
28 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
30 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
33 Etoposide phosphate Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
35 Analgesics Phase 3
36 Cyclooxygenase 2 Inhibitors Phase 3
37 Cyclooxygenase Inhibitors Phase 3
38 Analgesics, Non-Narcotic Phase 3
39 Peripheral Nervous System Agents Phase 3
40 Anti-Inflammatory Agents Phase 3
41 Anti-Inflammatory Agents, Non-Steroidal Phase 3
42 Antirheumatic Agents Phase 3
43 Folate Nutraceutical Phase 3,Phase 2,Phase 1
44 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
45 Shark Cartilage Nutraceutical Phase 3
46
Lenograstim Approved, Investigational Phase 2 135968-09-1
47
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
48
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
49
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
50
Mesna Approved, Investigational Phase 2 3375-50-6 598

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
3 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
4 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
5 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
6 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
7 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
8 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
9 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
12 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Unknown status NCT00227708 Phase 2 docetaxel
17 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
18 Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
19 Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC Completed NCT00030810 Phase 2 Taxotere/Cisplatin
20 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
21 Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab Completed NCT00387374 Phase 2 paclitaxel;carboplatin
22 Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00454194 Phase 2 pemetrexed disodium;sorafenib tosylate
23 Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00798603 Phase 2 carboplatin;pemetrexed disodium
24 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
25 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
26 Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00118183 Phase 2 docetaxel;bortezomib
27 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
28 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
29 SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002642 Phase 2 cisplatin;etoposide
30 Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer Completed NCT00003202 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
31 Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00023673 Phase 1, Phase 2 carboplatin;paclitaxel
32 Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00276588 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
33 Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT01302808 Phase 1, Phase 2 erlotinib hydrochloride;romidepsin
34 Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed NCT00346320 Phase 2
35 Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00293280 Phase 2 lomustine
36 Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00550537 Phase 2 bevacizumab;carboplatin;erlotinib hydrochloride;paclitaxel
37 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00006378 Phase 2 carboplatin;paclitaxel
38 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer Completed NCT00080938 Phase 2 Temozolomide
39 Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00077311 Phase 2 cisplatin;docetaxel;BNP7787
40 Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00025285 Phase 2 carboplatin;irinotecan hydrochloride;thalidomide
41 TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00036920 Phase 2 canfosfamide hydrochloride
42 Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer Completed NCT00006004 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
43 Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Completed NCT00005850 Phase 2 cisplatin;fluoxetine;gemcitabine hydrochloride
44 Icotinib for Completed Resected IB NSCLC With EGFR Mutation Recruiting NCT02264210 Phase 2 Icotinib
45 Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT01059188 Phase 2 cetuximab;cisplatin;docetaxel
46 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting NCT02186847 Phase 2 Carboplatin;Metformin Hydrochloride;Paclitaxel
47 Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
48 Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer Active, not recruiting NCT00126581 Phase 2 Carboplatin;Erlotinib Hydrochloride;Paclitaxel
49 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Active, not recruiting NCT00979212 Phase 2 panitumumab;carboplatin;paclitaxel
50 Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Terminated NCT00776100 Phase 2

Search NIH Clinical Center for Adenosquamous Cell Lung Carcinoma

Genetic Tests for Adenosquamous Cell Lung Carcinoma

Anatomical Context for Adenosquamous Cell Lung Carcinoma

MalaCards organs/tissues related to Adenosquamous Cell Lung Carcinoma:

41
Lung, Brain

Publications for Adenosquamous Cell Lung Carcinoma

Articles related to Adenosquamous Cell Lung Carcinoma:

# Title Authors Year
1
[Progression of diagnosis and treatment for adenosquamous lung carcinoma]. ( 28550661 )
2017
2
Surgical specimen histology revealed inadequacy of conventional transbronchial needle aspiration sample in the diagnosis of adenosquamous lung carcinoma. ( 25973234 )
2015
3
EGFR gene mutations in patients with adenosquamous lung carcinoma. ( 24575772 )
2014
4
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma. ( 24838432 )
2014
5
Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. ( 24481316 )
2014
6
Adenosquamous lung carcinoma: clinical characteristics, surgical treament and prognosis. ( 12906147 )
2000

Variations for Adenosquamous Cell Lung Carcinoma

Cosmic variations for Adenosquamous Cell Lung Carcinoma:

9
(show top 50) (show all 548)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6966579 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 7
2 COSM6953383 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 7
3 COSM6980872 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 7
4 COSM95548 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 7
5 COSM95544 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 7
6 COSM6980399 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.233G>A p.W78* 11:32434909-32434909 7
7 COSM6938307 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1156A>T p.K386* 11:32392044-32392044 7
8 COSM95531 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 7
9 COSM95521 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 7
10 COSM95485 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 7
11 COSM95476 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 7
12 COSM96265 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64I 17:60301699-60301699 7
13 COSM94159 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 8:102326590-102326590 7
14 COSM94158 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 8:102305221-102305221 7
15 COSM6983597 U2AF1 lung,NS,carcinoma,undifferentiated carcinoma c.319G>C p.D107H 21:43095467-43095467 7
16 COSM95420 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 19:10350838-10350838 7
17 COSM6942934 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.1922C>T p.S641L 14:81143980-81143980 7
18 COSM6953382 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.937A>C p.K313Q 14:81142995-81142995 7
19 COSM6966576 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.412C>T p.L138F 14:81091088-81091088 7
20 COSM6980873 TSC2 lung,NS,carcinoma,undifferentiated carcinoma c.1840G>T p.A614S 16:2071510-2071510 7
21 COSM6980394 TSC1 lung,NS,carcinoma,undifferentiated carcinoma c.694G>T p.E232* 9:132921406-132921406 7
22 COSM6980408 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1193C>T p.P398L 16:2173978-2173978 7
23 COSM6940747 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1287C>G p.Y429* 16:2174274-2174274 7
24 COSM95390 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 1:211356392-211356392 7
25 COSM22908 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.376-1G>T p.? 17:7675237-7675237 7
26 COSM11232 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.842A>G p.D281G 17:7673778-7673778 7
27 COSM45304 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.375+1G>A p.? 17:7675993-7675993 7
28 COSM10768 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 17:7675077-7675077 7
29 COSM10742 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.578A>G p.H193R 17:7674953-7674953 7
30 COSM11333 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.499C>T p.Q167* 17:7675113-7675113 7
31 COSM10779 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.818G>T p.R273L 17:7673802-7673802 7
32 COSM11354 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.991C>T p.Q331* 17:7673537-7673537 7
33 COSM11073 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.1024C>T p.R342* 17:7670685-7670685 7
34 COSM6815 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.461G>T p.G154V 17:7675151-7675151 7
35 COSM43750 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.811G>T p.E271* 17:7673809-7673809 7
36 COSM6913 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.783-1G>T p.? 17:7673838-7673838 7
37 COSM10645 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.527G>T p.C176F 17:7675085-7675085 7
38 COSM44295 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.993+1G>A p.? 17:7673534-7673534 7
39 COSM13584 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.919+1G>T p.? 17:7673700-7673700 7
40 COSM10660 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.818G>A p.R273H 17:7673802-7673802 7
41 COSM43753 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.560-1G>A p.? 17:7674972-7674972 7
42 COSM44240 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.514G>T p.V172F 17:7675098-7675098 7
43 COSM44891 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.796G>T p.G266* 17:7673824-7673824 7
44 COSM10889 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.536A>G p.H179R 17:7675076-7675076 7
45 COSM10714 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.473G>T p.R158L 17:7675139-7675139 7
46 COSM95367 TLR5 lung,NS,carcinoma,undifferentiated carcinoma c.1A>G p.M1V 1:223113031-223113031 7
47 COSM95359 TLR4 lung,NS,carcinoma,undifferentiated carcinoma c.337C>A p.P113T 9:117712465-117712465 7
48 COSM95356 TLR2 lung,NS,carcinoma,undifferentiated carcinoma c.1169A>G p.Q390R 4:153704076-153704076 7
49 COSM95347 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.1087C>T p.P363S 9:35721665-35721665 7
50 COSM95342 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.5624C>T p.S1875L 9:35705660-35705660 7

Expression for Adenosquamous Cell Lung Carcinoma

Search GEO for disease gene expression data for Adenosquamous Cell Lung Carcinoma.

Pathways for Adenosquamous Cell Lung Carcinoma

Pathways related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 ARAF EGFR ERBB2 FGFR3 HRAS KIF5B
2
Show member pathways
14.09 ARAF CD74 EGFR ERBB2 FGFR3 HRAS
3
Show member pathways
13.92 ALK ARAF DDR2 EGFR ERBB2 FGFR3
4
Show member pathways
13.79 ALK ARAF DDR2 EGFR ERBB2 FGFR3
5
Show member pathways
13.77 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
6
Show member pathways
13.75 ALK ARAF DDR2 EGFR ERBB2 FGFR3
7
Show member pathways
13.64 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
8
Show member pathways
13.58 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
9
Show member pathways
13.53 CD74 EGFR ERBB2 FGFR3 HRAS KIF5B
10
Show member pathways
13.49 ALK ARAF DDR2 EGFR ERBB2 FGFR3
11
Show member pathways
13.47 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
12
Show member pathways
13.41 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
13
Show member pathways
13.36 EGFR ERBB2 FGFR3 HRAS KRAS NRG1
14
Show member pathways
13.36 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
15
Show member pathways
13.22 ALK ARAF DDR2 EGFR ERBB2 FGFR3
16
Show member pathways
13.17 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
17
Show member pathways
13.15 ARAF EGFR FGFR3 HRAS KRAS NRG1
18
Show member pathways
13.15 ALK DDR2 EGFR FGFR3 HRAS KRAS
19
Show member pathways
13.08 EGFR ERBB2 FGFR3 HRAS KRAS PDGFRA
20
Show member pathways
13.06 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
21
Show member pathways
13.01 ARAF EGFR ERBB2 HRAS KRAS PDGFRA
22
Show member pathways
13 ARAF EGFR HRAS KRAS PDGFRA PIK3CA
23
Show member pathways
12.99 ARAF EGFR ERBB2 HRAS KRAS PIK3CA
24
Show member pathways
12.95 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
25
Show member pathways
12.94 ARAF EGFR ERBB2 HRAS KRAS PDGFRA
26
Show member pathways
12.89 ARAF EGFR ERBB2 HRAS KRAS NRG1
27 12.88 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
28
Show member pathways
12.87 ARAF EGFR ERBB2 HRAS KRAS PIK3CA
29
Show member pathways
12.83 EGFR FGFR3 HRAS KRAS PDGFRA PIK3CA
30
Show member pathways
12.79 ERBB2 HRAS KRAS NRG1 PIK3CA
31
Show member pathways
12.77 EGFR ERBB2 FGFR3 HRAS KRAS NRG1
32
Show member pathways
12.74 ARAF EGFR HRAS KRAS PDGFRA
33 12.72 ARAF EGFR FGFR3 HRAS KRAS PDGFRA
34
Show member pathways
12.71 EGFR ERBB2 HRAS KRAS PDGFRA PIK3CA
35 12.68 ALK ARAF EGFR ERBB2 FGFR3 HRAS
36
Show member pathways
12.67 EGFR HRAS PDGFRA PIK3CA
37
Show member pathways
12.63 ARAF EGFR ERBB2 HRAS KRAS NRG1
38
Show member pathways
12.59 FGFR3 HRAS KRAS PIK3CA
39 12.59 EGFR ERBB2 FGFR3 HRAS KRAS PDGFRA
40
Show member pathways
12.55 ARAF HRAS KRAS PIK3CA
41
Show member pathways
12.54 ARAF EGFR ERBB2 HRAS KRAS NRG1
42
Show member pathways
12.52 ERBB2 HRAS KRAS PIK3CA
43
Show member pathways
12.52 EGFR HRAS KRAS PDGFRA PIK3CA
44
Show member pathways
12.52 ALK ARAF EGFR ERBB2 FGFR3 HRAS
45 12.51 EGFR FGFR3 HRAS KIF5B PDGFRA
46
Show member pathways
12.5 EGFR ERBB2 FGFR3 HRAS KRAS PDGFRA
47
Show member pathways
12.48 FGFR3 HRAS KRAS PIK3CA
48 12.47 HRAS KRAS PDGFRA PIK3CA
49
Show member pathways
12.45 EGFR HRAS KRAS PIK3CA
50
Show member pathways
12.45 ARAF HRAS KRAS PIK3CA

GO Terms for Adenosquamous Cell Lung Carcinoma

Cellular components related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.91 ALK ARAF CD74 EGFR ENO2 ERBB2
2 perinuclear region of cytoplasm GO:0048471 9.83 EGFR ERBB2 HRAS KIF5B ROS1
3 integral component of plasma membrane GO:0005887 9.81 ALK DDR2 EGFR ERBB2 FGFR3 NRG1
4 cell surface GO:0009986 9.8 CD74 EGFR FGFR3 PDGFRA ROS1
5 plasma membrane GO:0005886 9.8 ALK CD74 DDR2 EGFR ENO2 ERBB2
6 receptor complex GO:0043235 9.23 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
7 cytoplasm GO:0005737 10.17 ALK DDR2 EGFR ENO2 ERBB2 FGFR3
8 membrane GO:0016020 10.13 ALK CD74 DDR2 EGFR ENO2 ERBB2

Biological processes related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol phosphorylation GO:0046854 9.99 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
2 positive regulation of protein phosphorylation GO:0001934 9.98 CD74 EGFR ERBB2 HRAS KRAS
3 peptidyl-tyrosine phosphorylation GO:0018108 9.97 ALK DDR2 EGFR ERBB2 FGFR3 NRG1
4 leukocyte migration GO:0050900 9.96 CD74 HRAS KRAS PIK3CA
5 positive regulation of cell migration GO:0030335 9.96 EGFR HRAS PDGFRA RET
6 wound healing GO:0042060 9.92 EGFR ERBB2 NRG1 PDGFRA
7 positive regulation of MAP kinase activity GO:0043406 9.9 EGFR ERBB2 HRAS KRAS
8 epidermal growth factor receptor signaling pathway GO:0007173 9.89 EGFR HRAS KRAS PIK3CA
9 positive regulation of fibroblast proliferation GO:0048146 9.88 CD74 DDR2 EGFR PDGFRA
10 ERBB2 signaling pathway GO:0038128 9.88 EGFR ERBB2 HRAS KRAS NRG1 PIK3CA
11 activation of MAPK activity GO:0000187 9.86 ALK CD74 NRG1
12 liver development GO:0001889 9.85 EGFR KRAS PIK3CA
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 ARAF EGFR PIK3CA
14 signal transduction by protein phosphorylation GO:0023014 9.85 EGFR ERBB2 ROS1
15 positive regulation of MAPK cascade GO:0043410 9.85 ALK CD74 DDR2 EGFR ERBB2 FGFR3
16 positive regulation of epithelial cell proliferation GO:0050679 9.83 EGFR ERBB2 HRAS
17 positive regulation of DNA replication GO:0045740 9.82 EGFR HRAS PDGFRA
18 regulation of cell motility GO:2000145 9.81 EGFR ERBB2 NRG1
19 regulation of ERK1 and ERK2 cascade GO:0070372 9.8 EGFR ERBB2 ROS1
20 negative regulation of ERBB signaling pathway GO:1901185 9.79 EGFR ERBB2 NRG1
21 regulation of TOR signaling GO:0032006 9.68 ARAF ROS1
22 chondrocyte proliferation GO:0035988 9.68 DDR2 FGFR3
23 response to isolation stress GO:0035900 9.67 HRAS KRAS
24 endochondral bone growth GO:0003416 9.66 DDR2 FGFR3
25 negative regulation of signal transduction GO:0009968 9.61 ALK ARAF DDR2 EGFR ERBB2 FGFR3
26 positive regulation of kinase activity GO:0033674 9.28 ALK CD74 DDR2 EGFR ERBB2 FGFR3
27 signal transduction GO:0007165 10.29 ALK ARAF CD74 DDR2 EGFR ERBB2
28 cell differentiation GO:0030154 10.22 ALK ARAF DDR2 EGFR ERBB2 FGFR3
29 multicellular organism development GO:0007275 10.21 ALK ARAF DDR2 EGFR ERBB2 FGFR3
30 phosphorylation GO:0016310 10.19 ALK ARAF DDR2 EGFR ERBB2 FGFR3
31 protein phosphorylation GO:0006468 10.16 ALK ARAF DDR2 EGFR ERBB2 FGFR3
32 negative regulation of apoptotic process GO:0043066 10.13 ALK ARAF CD74 DDR2 EGFR ERBB2
33 positive regulation of cell proliferation GO:0008284 10.11 DDR2 EGFR FGFR3 HRAS KRAS NRG1
34 cell proliferation GO:0008283 10.08 ALK CD74 EGFR ERBB2 HRAS ROS1
35 positive regulation of gene expression GO:0010628 10.04 ERBB2 HRAS KRAS NRG1 RET
36 axon guidance GO:0007411 10.02 HRAS KIF5B KRAS PIK3CA RET
37 protein autophosphorylation GO:0046777 10.02 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
38 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.02 ALK DDR2 EGFR ERBB2 PDGFRA RET
39 MAPK cascade GO:0000165 10.02 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
40 positive regulation of protein kinase B signaling GO:0051897 10.01 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
41 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 ALK ARAF CD74 DDR2 EGFR ERBB2

Molecular functions related to Adenosquamous Cell Lung Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.95 EGFR ERBB2 FGFR3 NRG1 PDGFRA RET
2 protein tyrosine kinase activity GO:0004713 9.91 ALK DDR2 EGFR ERBB2 FGFR3 NRG1
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.85 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
4 MAP kinase kinase kinase activity GO:0004709 9.81 ALK ARAF DDR2 EGFR ERBB2 FGFR3
5 protein phosphatase binding GO:0019903 9.71 EGFR ERBB2 ROS1
6 mitogen-activated protein kinase kinase binding GO:0031434 9.61 ALK ARAF DDR2 EGFR ERBB2 FGFR3
7 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.56 EGFR ERBB2
8 ErbB-3 class receptor binding GO:0043125 9.52 ERBB2 NRG1
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.23 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
10 protein binding GO:0005515 10.42 ALK ARAF CD74 DDR2 EGFR ENO2
11 ATP binding GO:0005524 10.24 ALK ARAF DDR2 EGFR ERBB2 FGFR3
12 transferase activity GO:0016740 10.21 ALK ARAF DDR2 EGFR ERBB2 FGFR3
13 nucleotide binding GO:0000166 10.06 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
14 protein kinase activity GO:0004672 10.06 ALK ARAF DDR2 EGFR ERBB2 FGFR3
15 identical protein binding GO:0042802 10.04 ALK CD74 EGFR ERBB2 FGFR3 KIF5B
16 transmembrane signaling receptor activity GO:0004888 10.03 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
17 kinase activity GO:0016301 10.02 ALK ARAF DDR2 EGFR ERBB2 FGFR3

Sources for Adenosquamous Cell Lung Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....